Skip to main content
NCBI home page
BMC Cancer logoLink to BMC Cancer
. 2022 Nov 28;22:1224. doi: 10.1186/s12885-022-10335-7

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

C Martínez-Laperche 1,2, L Sanz-Villanueva 1,2, F J Díaz Crespo 1,3, P Muñiz 1,2, R Martín Rojas 2, D Carbonell 1,2, M Chicano 1,2, J Suárez-González 1,4, J Menárguez 1,3, M Kwon 1,2, J L Diez Martín 1,2,5, I Buño 1,2,4,6, M Bastos Oreiro 1,2,✉
PMCID: PMC9703722  PMID: 36443715

Correction: BMC Cancer 22, 982 (2022)

https://doi.org/10.1186/s12885-022-10070-z

Following publication of the original article [1], the authors identified an error in Fig. 1B. Patients with EZH2 mutation (n=7) have worse prognosis than patients without mutation (n=23). The updated Fig. 1 is supplied in this correction article.

Fig. 1.

Fig. 1

Open in a new tab

Kaplan-Meier curves in patients with grade 1, 2, and 3a. A PFS and OS in patients treated with R-CHOP (EZH2 mutated vs. unmutated); B PFS and OS in patients treated with R-Bendamustine (EZH2 mutated vs. unmutated). C PFS and OS in EZH2 mutated patients (R-CHOP vs. R-Bendamustine). PFS Progression-free survival. OS: Overall survival

The original article [1] has been corrected.

Reference

  • 1.Martínez-Laperche C, Sanz-Villanueva L, Díaz Crespo FJ, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22:982. doi: 10.1186/s12885-022-10070-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES